Table 3.
Expression of CD56 in biliary atresia n (%)
| Stage of BA | n | CD56++ | CD56+ | CD56- |
| All | 55 | 27 (49.1) | 14 (25.5) | 14 (25.5) |
| BA-E without bile plugs | 6 | 1 (16.7) | 2 (33.3) | 3 (50.0) |
| BA-E with bile plugs | 21 | 10 (47.6) | 5 (23.8) | 6 (28.6) |
| BA-ML without bile plugs | 6 | 4 (66.7) | 1 (16.7) | 1 (16.7) |
| BA-ML with bile plugs | 22 | 12 (54.5) | 6 (27.3) | 4 (18.2) |
| All BA-E | 27 | 11 (40.7) | 7 (25.9) | 9 (33.3) |
| All BA-ML | 28 | 16 (57.1) | 7 (25.0) | 5 (17.9) |
| All without bile plugs | 12 | 5 (41.7) | 3 (25.0) | 4 (33.3) |
| All with bile plugs | 43 | 22 (51.2) | 11 (25.6) | 10 (23.3) |
BA: Biliary atresia; BA-E: Early stage of BA with less tissue fibrosis; BA-ML: Middle or late stage BA with more extensive or dense tissue fibrosis.